Ken Griffin’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,500
Closed -$322K – 13933
2026
Q2
$322K Buy
+11,500
New +$324K ﹤0.01% 10968
2025
Q2
– Sell
-4,500
Closed -$145K – 12474
2025
Q1
$145K Hold
4,500
– – ﹤0.01% 10926
2024
Q4
$138K Sell
4,500
-2,700
-38% -$86.8K ﹤0.01% 11016
2024
Q3
$202K Buy
7,200
+3,600
+100% +$88.7K ﹤0.01% 10135
2024
Q2
$82K Sell
3,600
-500
-12% -$11.5K ﹤0.01% 11181
2024
Q1
$125K Buy
4,100
+2,400
+141% +$80.4K ﹤0.01% 11057
2023
Q4
$60.7K Buy
+1,700
New +$63.2K ﹤0.01% 11582
2023
Q3
– Sell
-300
Closed -$14.8K – 14254
2023
Q2
$14.8K Buy
+300
New +$13.8K ﹤0.01% 12987
2021
Q3
– Sell
-5,000
Closed -$397K – 13772
2021
Q2
$397K Sell
5,000
-1,800
-26% -$131K ﹤0.01% 10578
2021
Q1
$446K Buy
+6,800
New +$419K ﹤0.01% 9929
2020
Q4
– Sell
-6,700
Closed -$267K – 10887
2020
Q3
$267K Buy
6,700
+1,200
+22% +$50.9K ﹤0.01% 8333
2020
Q2
$247K Buy
+5,500
New +$239K ﹤0.01% 8224
2015
Q4
– Sell
-500
Closed -$11K – 8911
2015
Q3
$11K Buy
+500
New +$12.5K ﹤0.01% 8629

Other funds holding ATRC

Ken Griffin's ATRC Position: Q3 2026 in Review

Ken Griffin increased its AtriCure (ATRC) stake by 220% in Q3 2026, buying an estimated $17.6M and bringing the position to 567,483 shares worth $31.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Ken Griffin first reported a position in ATRC in Q4 2013 and has held it in 42 quarters since. The position peaked at $65.8M in Q2 2021. 286 funds tracked by Wall St. Rank hold ATRC as of Q3 2026.

  • Ken Griffin held 567,483 shares of AtriCure worth $31.9M as of Q3 2026.
  • Ken Griffin bought 390,144 AtriCure shares in Q3 2026, an estimated $17.6M.
  • AtriCure made up ﹤0.01% of Ken Griffin's portfolio in Q3 2026, its #2020 holding.
  • Ken Griffin first reported a position in AtriCure in Q4 2013 and has held it in 42 quarters since.
  • Ken Griffin's AtriCure position peaked at $65.8M in Q2 2021.
  • 286 funds tracked by Wall St. Rank held AtriCure as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.